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Capecitabine, a prodrug of 5-FU, has been reported to generate maximal tumour activity at tumour sites and/or to improve drug
tolerability as compared with 5-FU infusion, and it has also been demonstrated to act synergistically with irinotecan against some solid
cancers. A previous study concluded that dose-intensified biweekly capecitabine seems to be more effective at increasing both
response rate and progression-free survival time than conventional dose and schedule of capecitabine in colon cancer. We
conducted this study to ascertain the efficacy and toxicity of dose-intensified biweekly capecitabine and irinotecan combination
chemotherapy in chemotherapy-naı ¨ve advanced or metastatic gastric cancer patients. Patients were treated with irinotecan
130mgm
 2 intravenously for 90min on days 1 and 15. Capecitabine at 3500mgm
 2day
 1, divided into two sessions per day, was
administered for seven consecutive days from days 1 and 15, and followed by a 7-day drug-free period, respectively. Fifty-five eligible
patients were enrolled in this study from November 2003 to April 2006. There were 22 women and 33 men: median patient age was
54 years (range: 27–81). A total of 200 treatment cycles were administered at a median number of four per patient (range: 1–9).
Intent-to-treatment analysis showed that one patient achieved complete response (1.8%), 23 partial response (41.8%), 15 stable
disease (27.3%), 10 progressive disease (18.2%) and 6 were non-evaluable (10.9%). The overall response rate was 43.6% (95%
confidence interval: 30.2–56.9). The common grade 3–4 toxicities were neutropenia in 12 (21.8%), nausea/vomiting in 3 (5.4%) and
diarrhea in 4 (7.2%) patients. Median time to progression was 5 months (range: 0.5–11 months), median survival duration was 11
months (range: 0.5–45 months) and median response duration was 6 months (range: 0.5–9 months). Biweekly dose-intensified
capecitabine and irinotecan combination chemotherapy was active for the treatment of advanced or metastatic gastric cancers with a
tolerable safety profile.
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Gastric cancer is the second most common cancer and one of
the most common causes of cancer mortality in the world (Boring
et al, 1994; Shin et al, 2005; Kamangar et al, 2006). Despite
reducing gastric cancer incidence in the Occident, the incidence of
cardiac and gastroesophageal junctional adenocarcinoma has
increased, and the 5-year survival rate for advanced gastric cancer
has not significantly changed (Brown and Devesa, 2002). The only
curative treatment modality for gastric cancer is surgery. However,
many patients present with advanced stage disease, and the relapse
rate of those who are subjects for curative resection is high, at
around 65% (Hartgrink et al, 2004). Thus, most gastric cancer
patients are subjects for systemic chemotherapy. Current response
rates to chemotherapy among advanced gastric cancer patients are
between 10 and 20% for a single agent and between 30 and 50% for
combination chemotherapy (Barone et al, 1998; Ajani et al, 2005;
Moehler et al, 2005; Ohtsu et al, 2006; Nardi et al, 2007). However,
during recent years, several new agents, for example, taxane,
irinotecan and oxaliplatin, have been introduced for the treatment
of gastric cancer (Louvet et al, 2002; Pozzo et al, 2004; Roth et al,
2004), and these drugs have shown promising response rates
without sacrificing acceptable toxicity.
Irinotecan (Camptor
s; Pfizer) is a semisynthetic plant alkaloid
camptothecin, which inhibits DNA topoisomerase-I. SN-38 has
been identified to be the important metabolite of irinotecan, and
to inhibit the regulation of DNA during cell replication. In
recent meta-analysis of chemotherapies used to treat advanced
gastric cancer, a comparison between irinotecan-containing versus
nonirinotecan-containing combinations (mainly 5-FU/cisplatin)
showed a non-survival benefit in favour of irinotecan-containing
regimens (HR¼0.88) (Wagner et al, 2006).
Capecitabine (Xeloda
s; Roche) is an oral fluoropyrimidine
that selectively generates higher levels of 5-FU in cancer tissues
than in normal tissues via the action of thymidine phosphorylase.
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advanced gastric cancer with the response rate of from 19.4 to
34% (Koizumi et al, 2003; Hong et al, 2004); moreover, median
survival duration in these studies was comparable to other double
or triple combination chemotherapies. Capecitabine has the
advantages of convenient oral administration and of mimicking
the effect of protracted intravenous (i.v.) 5-FU.
Irinotecan and capecitabine in combination could be possible to
have a synergistic effect in previous pre-clinical and clinical
studies (Guichard et al, 1998; Mullany et al, 1998; Azrak et al, 2004;
Cao et al, 2005; Rea et al, 2005). Irinotecan reduces DNA synthesis,
increases dTTP pools and inhibits dUMP synthesis, which are
also associated with the antitumour activity of capecitabine
(Mullany et al, 1998). Actually, irinotecan/capecitabine combina-
tion regimens have been used to treat several types of
solid tumours (Borner et al, 2005; Han et al, 2005; Kim et al,
2005; Baek et al, 2006).
However, no optimum schedule has been identified for these
two drugs. This is the first trial of high-dose regimen compared
to usual capecitabine schedules and it is biweekly rather than
triweekly against advanced gastric cancer. A preclinical study
using human tumour xenografts indicated that tumour growth
inhibition depends on the total dose of capecitabine administered
and not on the dosing schedule (Van Cutsem et al, 2000), because
short-term intermittent rather than prolonged or continuous
administration may allow capecitabine dose intensities to be
increased (and thus antitumour efficacies) without increasing
toxicity via the incorporation of longer drug-free intervals.
Actually, this dose-intensified biweekly administration seems to
be more effective at increasing response rate and progression-free
survival than conventional dose and schedule of capecitabine in
colon cancer, without compromising its safety profile, despite the
fact that capecitabine was administered with oxaliplatin (Thomas
et al, 2001; Scheithauer et al, 2002, 2003). In addition, favourable
results were reported for higher cumulative doses of oral
capecitabine in advanced gastroesophageal cancer, although the
administration schedule used differed from that used in the
present study (Van Cutsem et al, 2000).
Here, we report the findings of a phase II study that was
undertaken to evaluate the efficacy and toxicity of biweekly
irinotecan and high-dose capecitabine combination chemotherapy
for the treatment of advanced and/or metastatic gastric cancer in a
first-line treatment setting.
PATIENTS AND METHODS
Between November 2003 and January 2006, 55 patients were
enrolled in this trial. Written informed consent was obtained from
all study subjects, and the study protocol was approved by our
institutional review board. All patients had histologically proven
gastric adenocarcinoma and locally unresectable or recurrent/
metastatic disease. Only patients with measurable disease were
accepted. The eligibility requirements included a performance
status of p2 and a life expectancy of at least 12 weeks. Preclinical
laboratory parameters included an absolute neutrophil count
of 41.5 10
3l
 1 and a platelet count of 4100 10
3/l
 1. Patients
were required to have normal cardiac, renal and hepatic functions.
Contraindications to entry included any active infectious process,
active heart disease or any concomitant second primary cancer.
Patients who had undergone previous chemotherapy, except
adjuvant chemotherapy completed within 6 months before
enrollment, were also excluded.
Treatment
Irinotecan 130mgm
 2 was administrated i.v. for 90min on days 1
and 15. Capecitabine 3500mgm
 2day
 1 b.i.d. was administered
for seven consecutive days from days 1 and 15, which was followed
by a 7-day drug-free interval, respectively.
If a patient developed neutropenia (an absolute neutrophil count
of o1000) of 45 days duration or febrile neutropenia, irinotecan
and capecitabine dosages were reduced by 25% during subsequent
treatment cycles. Treatment was interrupted when a patient had a
non-haematologic toxicity of 4grade 2 during treatment, and
restarted at a 25% reduced dosage after the toxicity had resolved to
a level of ograde 2. If a patient had severe toxicity at the time of a
scheduled retreatment, drug administration was postponed until
the toxicity had resolved. If drug administration was delayed for
more than 3 weeks, the patient was excluded from the study. When
a patient had diarrhea, oral loperamide was immediately started at
2mg, and subsequently 1mg was given every 2h until symptoms
were relieved. Acute onset diarrhea that occurred within 24h
was considered as a cholinergic symptom and was prevented
with atropine. This above cycle was repeated every 4 weeks until
tumour progression or the development of treatment intolerance.
Evaluation
All patients were examined clinically before enrolment by
laboratory evaluation, which included a complete blood cell count
and electrolytes, blood urea nitrogen, creatinine, calcium, phos-
phorous, bilirubin, alkaline phosphatase, aspartate aminotrans-
ferase, alanine aminotransferase, total proteins and albumin.
Upper gastrointestinal endoscopy, abdominal-computed tomogra-
phy and other appropriate procedures were also performed.
Complete blood cell counts were examined on days 1 and 14 of
every cycle, and chest radiography, liver function tests, blood urea
nitrogen, creatinine and electrolyte were examined on day 28 of
every cycle. Examination of the evaluable parameters such as
abdominal-computed tomography for evaluating of response was
done after every two cycles of treatment. Response evaluation
criteria in solid tumours were adopted to evaluate treatment
response (Therasse et al, 2000). Toxicity was reported using a
World Health Organization (WHO) Toxicity Criteria
Statistical analysis
Response rate was used as the primary end point in the present
study, and a response rate of 40% was anticipated. A response rate
of 20% was considered to be the minimum level for continuing the
study. The a-level of the design used was 0.05 and its power was
0.9. The number of subjects was calculated using the Simon two-
stage optimal Minimax design (Simon, 1989). A total of 45
evaluable patients were needed; 24 patients were planned for stage
1 and 21 for stage 2. If five or fewer responses had been observed
during stage 1, then the trial would have been stopped. The
proportion of patients who responded to treatment was used to
estimate the true response rate with a 95% confidence interval
(CI). Actuarial survival duration was determined using the
Kaplan–Meier method. Response duration was calculated from
the date of response confirmation to the date when disease
progression was first observed. Survival duration was calculated
from the first day of treatment until death or last follow-up. Time
to disease progression was calculated from the first day of
treatment to the date when disease progression was first observed.
RESULTS
Patient’s characteristics
Fifty-five patients were enrolled in this trial. Patient characteristics
are listed in Table 1. All patients were evaluable for toxicity, but
only 49 patients (after excluding three patients who withdrew
consent and three patients who failed to continue treatment due to
adverse events after one cycle of chemotherapy) were evaluable.
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Thirty-three patients were male and 22 were female. All patients
had a good performance status of ograde 2. Twelve patients had a
history of surgery (with curative intent for eight patients and with
palliative intent for four), and only four patients had received
adjuvant chemotherapy. Forty-three patients were treatment na ¨ive.
Response to chemotherapy
Fifty-five enrolled patients received 200 chemotherapy cycles; a
median number of four per patient, which ranged from one to nine
(Table 2). Six patients were non-evaluable; three patients refused
further treatment after one cycle of chemotherapy and asked to be
referred to other hospital, and treatment was discontinued in three
patients due to toxicity after one cycle of chemotherapy. However,
all six were included in the toxicity evaluation and in response rate
calculations. By intention-to-treat analysis, one of the 55 patients
achieved complete response (1.8%) and 23 showed partial response
(41.8%). The overall objective response rate was 43.6% (95% CI:
30.2–56.9%) with a median response duration of 6 months (range:
0.5–9 months). Fifteen patients (27.3%) had stable disease and
10 patients (18.2%) had disease progression as a best response.
Median time to progression was 5 months (range: 0.5–11
months), and median survival duration was 11 months (range:
0.5–45 months).
Toxicity
Fifty-five patients were evaluable for toxicities (Table 3). The most
commonly encountered haematologic grade 3 or 4 toxicity on
irinotecan/capecitabine was neutropenia. Grades 3 and 4 neutro-
penia were experienced by eight (14.5%) and four patients (7.3%),
respectively. Grades 3 and 4 anemia were also observed in five
(9.1%) and one patient (1.8%), respectively. The most common
non-haematologic toxicity was diarrhea. Grades 3 and 4 diarrhea
both occurred in two patients (3.6%).
Fourteen patients required irinotecan and capecitabine dose
modifications. Of these, the most common causes of dose
reduction were prolonged grade 3 or 4 neutropenia in five
patients. Other causes of dose reduction were grade 3 or 4 nausea/
vomiting in one patient, grade 4 diarrhea in one patient and grade
3 fatigue in one patient. Another five patients had a capecitabine
dose modification. The most common causes of these dose
reductions were grade 2 or 3 hand/foot syndrome in three
patients. Another two patients underwent capecitabine dose
reduction due to investigator discretion for grade 3 fatigue in
one patient and grade 3 hepatitis in the other. Three patients
discontinued treatment due to toxicity after one cycle of
chemotherapy; grade 3 ischemic colitis in one, bowel perforation
in one and death from pneumonia in one. In total nine (4.5%)
cycles were delayed. The most common cause of treatment delay
was neutropenia in four patients; other causes were nausea/
vomiting in three patients, fatigue in one and fever in one.
The mean dose intensities of irinotecan and capecitabine
were 61.5mgm
 2week
 1 and 11343mgm
 2week
 1, respectively,
which were 94.7 and 92.6% of their respective intended doses
(Figure 1).
DISCUSSION
Pozzo et al (2004) compared irinotecan/cisplatin and irinotecan/5-
FU/leucovorin with the aim of selecting a better regimen for a
comparative phase III study with cisplatin/5-FU for the treatment
of advanced gastric cancer, and the overall response rate of the
irinotecan/5-FU/leucovorin arm (42%) was found to be superior to
that of the irinotecan/cisplatin arm (32%). In the present study, we
used capecitabine instead of 5-FU and leucovorin. Capecitabine
is an oral fluoropyrimidine, and selectively produces higher con-
centrations of 5-FU in tumour tissues than in normal tissues. Hong
et al (2004) studied capecitabine monotherapy for the treatment of
advanced gastric cancer, and used capecitabine at 1250mgm
 2
twice daily (2500mgm
 2day
 1) for 14 days followed by 7 days of
Table 1 Patient characteristics
Total no. of patients 55
No. of evaluable patients 49
Median age in year 54
Range 25–81
Male/Female 33/22
ECOG performance status
03
14 1
21 1
Previous treatment
None 43
Operation 12
Palliative/curative 4/8
Chemotherapy 4
IP/adjuvant 2/2
Table 2 Treatment response in gastric cancer patients
Total no. chemotherapy cycles 200
Median 4
Range 1–9
Dose delivery
Irinotecan (%) 94.7
Capecitabine (%) 92.6
Enrolled patients 55
Response (%)
CR 1 (1.8)
PR 23 (41.8)
SD 15 (27.3)
PD 10 (18.2)
NE 6 (10.9)
Overall response (95% CI) 43.6% (30.2–56.9%)
Median time to progression, month (range) 5 (0.5–11)
Median survival duration, month (range) 11 (0.5–45)
Median response duration, month (range) 6 (0.5–9)
Table 3 Major toxicities – WHO criteria (N¼55)
Number of patients (%)
Toxicity Grade 1/2 3 4
Neutropenia 13 (23.6) 8 (14.5) 4 (7.3)
Thrombocytopenia 2 (3.6) 1 (1.8) 1 (1.8)
Anemia 16 (29.1) 5 (9.1) 1 (1.8)
Mucositis 3 (5.4) 0 2 (3.6)
Diarrhea 15 (27.3) 2 (3.6) 2 (3.6)
Nausea/vomiting 15 (27.3) 2 (3.6) 1 (1.8)
Hepatotoxicity 2 (3.6) 2 (3.6) 0
Hand–foot syndrome 6 (10.9) 3(5.5) —
Alopecia 14 (25.5) 3 (5.5) 0
Fever 6 (10.9) 0 0
Nephropathy 1 (3.8) 0 0
Neuropathy 2 (3.6) 0 0
Fatigue 1 (1.9) 2 (3.6) 1 (1.8)
Colitis 0 2 (3.6) 0
Constipation 2 (3.6) 0 0
Infection 0 2 (3.6) 0
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disease were 34 and 30%, respectively, median time to progression
was 3.2 months and median overall survival was 9.5 months. The
most common toxicity was hand–foot syndrome, but grade 3 or
4 hand–foot syndrome was detected in only 9% of patients.
Different capecitabine schedules have been examined for the
treatment of advanced gastric cancer (Koizumi et al, 2003). In this
earlier study, capecitabine as a single agent was administered
at 828mgm
 2 b.i.d. for 3 weeks, followed by 1 week off, and a
response rate of 19% (95% CI: 7.5–37.5%) was observed in gastric
cancer. Median time to progression was 85 days and median
survival was 247.5 days. No toxicity of Xgrade 3 was reported, and
the toxicity of capecitabine appeared to be correlated with the drug
administration schedule.
The aim of this study was to determine the response rate and
toxicities of combined dose-intensified biweekly capecitabine and
irinotecan for the treatment of advanced gastric cancer. Capeci-
tabine in the combination chemotherapy was reported to be
at least as effective as 5-FU and leucovorin without additional
toxicity in a REAL-2 study (Sumpter et al, 2005). Moreover,
capecitabine has several advantages over i.v. 5-FU for clinical
applications – the first of which is convenience. Capecitabine
can be administered enterally without a portable infusion pump
and central venous line, which results in high drug compliance
and the maintenance of a constant 5-FU plasma level. The
second reason concerns its safety, that is, capecitabine can be
discontinued whenever severe toxicity develops, which prevents
toxicity-induced deterioration. Our results demonstrate that dose-
intensified biweekly capecitabine and irinotecan are active against
advanced gastric cancer with a 43% overall response rate (95% CI:
30.2–56.9%) and a median response duration of 6 months.
Moreover, the results achieved in this study could be favourably
comparable with those of other studies that used an irinotecan-
based combination regimen (Pozzo et al, 2004; Baek et al, 2006).
Biweekly irinotecan and capecitabine (180mgm
 2, day 1 and
2000mgm
 2, days 1–9, respectively) have also been studied
against gastroesophageal cancer (Burge et al, 2006), and an overall
response rate of 32% was obtained. Because previous studies have
produced improved results for dose-intensified biweekly capeci-
tabine against colorectal cancer, in the present study, we adopted
this dose and schedule for capecitabine instead of the conventional
triweekly regimen against gastric cancer. The dose-intensified
biweekly capecitabine arm showed a higher response rate (54.2 vs
42.2%) and a longer median progression-free survival time than
the low-dose arm (10.5 vs 6.0 months) without an increase in
toxicities (Van Cutsem et al, 2000; Scheithauer et al,2 0 0 3 ) .I nas t u d y
by Scheithauer et al, colorectal cancer patients received oxaliplatin
130mgm
 2 on day 1 plus capecitabine 2000mgm
 2day
 1 on days
1–14 every 3 weeks or oxaliplatin 85mgm
 2 on days 1 and 15
combined with capecitabine 3500mgm
 2 on days 1–7 and 15–21
every 4 weeks. However, no difference was found between the rates of
haematologic and non-haematologic toxicities for the biweekly and
triweekly regimens. Moreover, despite the use of a greater dose
intensity of capecitabine, toxicities were tolerable for most patients,
which were contrary to expectation (Kohne et al, 2005).
Clinical trials with novel drugs introduced to treat advanced
gastric cancer have prolonged survival time. In particular, taxane-
or oxaliplatin-based combination chemotherapies have shown
high response rates from 38 to 54% and a median overall survival
time of from 8.6 to 11.4 months against advanced gastric cancer
(Louvet et al, 2002; De Vita et al, 2005; Lordick et al, 2005; Van
Cutsem et al, 2006). Median survival duration in the present study
was 11 months, which is the highest recorded to date by gastric
cancer studies.
In the present study, neutropenia was the most common grade 3
or 4 haematologic toxicity, and was demonstrated in eight (14.5%)
and four (7.3%) patients, respectively. However, all these patients
recovered with supportive care based on, for example, the
administration of granulocyte colony stimulating factor.
As was expected, in the present study, the most common non-
haematologic toxicity was diarrhea, which occurred in 19 patients
(34.5%). However, grade 3 or 4 diarrhea occurred in only two
patients (3.6%) each. Moreover, this 7.2% rate of grade 3 or 4
diarrhea was less than that observed in other studies, which
reported rates of 15–22% (Kim et al, 2005; Baek et al, 2006; Burge
et al, 2006). The diarrhea and hand–foot syndrome were dose-
limiting toxicities in phase I studies using capecitabine (Budman
et al, 1998; Mackean et al, 1998). In the present study, nine patients
(16.4%) experienced any grade of hand–foot syndrome and only
three patients (5.5%) experienced grade 3 hand–foot syndrome.
The rate of hand–foot syndrome in the present study was
definitely lower than those of triweekly capecitabine studies,
which have reported rates between 40 and 71% (Park et al, 2004;
Baek et al, 2006). Despite a high mean dose intensity, the rates of
diarrhea and hand–foot syndrome in the present study were lower
than those of triweekly capecitabine studies (Hong et al, 2004;
Park et al, 2004; Han et al, 2005; Baek et al, 2006). The capecitabine
dose intensity used in the present study was 30% higher than that
used by Baek et al (i.e., 11343mgm
 2week
 1 in our study vs
8641mgm
 2week
 1 by Baek et al) and dose intensity was
maintained during continued treatment cycles. In addition, the
dose reduction rate in the present study (38.7%) was lower than
that found by Baek et al study (57%) (Baek et al, 2006). Given
higher dose intensities and uninterrupted treatment due to toxicity
development, biweekly dose-intensified capecitabine and irinote-
can combination chemotherapy appears to offer the possibility of
longer response and survival duration.
In conclusion, dose-intensified biweekly capecitabine and
irinotecan combination was found to be a moderately active
regimen against advanced gastric cancer with manageable toxicity.
The convenience of administering this regimen and the low rate of
non-haematologic toxicities encountered suggest that it should be
considered an option for the treatment of advanced gastric cancer.
Phase III-randomized clinical trials are warranted to compare the
efficacies and safety profiles of biweekly dose-intensified admin-
istration and conventional triweekly capecitabine.
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Figure 1 Proportion of delivered dose over planned dose per cycle and
per patient during respective treatment cycles.
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